Does ABIRATERONE Cause Second primary malignancy? 7 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with ABIRATERONE (Abiraterone Acetate). This represents 0.0% of all adverse event reports for ABIRATERONE.
7
Reports of Second primary malignancy with ABIRATERONE
0.0%
of all ABIRATERONE reports
0
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From ABIRATERONE?
Of the 7 reports, 1 (14.3%) required hospitalization, and 2 (28.6%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ABIRATERONE. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does ABIRATERONE Cause?
Death (5,623)
Fatigue (1,928)
Drug ineffective (1,732)
Therapy cessation (1,602)
Prostatic specific antigen increased (1,581)
Disease progression (1,098)
Hospitalisation (1,034)
Hot flush (989)
Asthenia (891)
Off label use (859)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ABIRATERONE Alternatives Have Lower Second primary malignancy Risk?
ABIRATERONE vs ABIRATERONE\ABIRATERONE
ABIRATERONE vs ABOBOTULINUMTOXINA
ABIRATERONE vs ABRAXANE
ABIRATERONE vs ABROCITINIB
ABIRATERONE vs ACALABRUTINIB